Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiology | 23 | 2023 | 530 | 2.270 |
Why?
|
| American Heart Association | 18 | 2023 | 310 | 1.630 |
Why?
|
| Cardiovascular Diseases | 18 | 2022 | 2195 | 1.630 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2022 | 849 | 1.160 |
Why?
|
| Hyperlipidemias | 7 | 2022 | 235 | 1.070 |
Why?
|
| Research Report | 5 | 2021 | 144 | 0.870 |
Why?
|
| Anticholesteremic Agents | 8 | 2022 | 256 | 0.850 |
Why?
|
| Primary Prevention | 2 | 2021 | 255 | 0.810 |
Why?
|
| Chest Pain | 5 | 2021 | 155 | 0.800 |
Why?
|
| Cholesterol | 5 | 2021 | 658 | 0.680 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 444 | 0.680 |
Why?
|
| Practice Guidelines as Topic | 9 | 2021 | 2403 | 0.640 |
Why?
|
| Cholesterol, LDL | 7 | 2022 | 565 | 0.640 |
Why?
|
| Aspirin | 1 | 2020 | 455 | 0.570 |
Why?
|
| Medication Adherence | 5 | 2022 | 492 | 0.570 |
Why?
|
| Consensus | 12 | 2022 | 978 | 0.570 |
Why?
|
| Societies, Medical | 6 | 2021 | 1335 | 0.560 |
Why?
|
| Secondary Prevention | 3 | 2021 | 329 | 0.520 |
Why?
|
| Ezetimibe | 4 | 2022 | 101 | 0.520 |
Why?
|
| Advisory Committees | 5 | 2019 | 203 | 0.510 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 598 | 0.470 |
Why?
|
| Hypercholesterolemia | 4 | 2018 | 259 | 0.450 |
Why?
|
| United States | 30 | 2023 | 15433 | 0.410 |
Why?
|
| Evidence-Based Medicine | 5 | 2021 | 1085 | 0.410 |
Why?
|
| Atherosclerosis | 4 | 2022 | 935 | 0.360 |
Why?
|
| Diabetes Mellitus | 3 | 2022 | 1054 | 0.340 |
Why?
|
| Awards and Prizes | 1 | 2010 | 98 | 0.340 |
Why?
|
| Coronary Artery Disease | 4 | 2021 | 1011 | 0.330 |
Why?
|
| Hypertension | 3 | 2022 | 1503 | 0.330 |
Why?
|
| Coronary Disease | 2 | 2010 | 764 | 0.320 |
Why?
|
| Risk Reduction Behavior | 4 | 2021 | 227 | 0.290 |
Why?
|
| Algorithms | 4 | 2021 | 3890 | 0.290 |
Why?
|
| Heart Valve Diseases | 2 | 2021 | 193 | 0.290 |
Why?
|
| Myocardial Infarction | 2 | 2010 | 1374 | 0.290 |
Why?
|
| Guideline Adherence | 2 | 2010 | 636 | 0.290 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 585 | 0.270 |
Why?
|
| Registries | 3 | 2021 | 2170 | 0.250 |
Why?
|
| Medication Therapy Management | 3 | 2018 | 36 | 0.230 |
Why?
|
| Hypolipidemic Agents | 2 | 2008 | 190 | 0.230 |
Why?
|
| Dyslipidemias | 2 | 2021 | 235 | 0.220 |
Why?
|
| Aortic Diseases | 2 | 2023 | 206 | 0.220 |
Why?
|
| Military Medicine | 1 | 2021 | 53 | 0.200 |
Why?
|
| Diet Therapy | 1 | 2021 | 52 | 0.190 |
Why?
|
| Heart Valves | 1 | 2021 | 66 | 0.190 |
Why?
|
| Cardiovascular System | 1 | 2022 | 145 | 0.190 |
Why?
|
| Nutrition Policy | 1 | 2021 | 111 | 0.190 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 104 | 0.190 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 97 | 0.180 |
Why?
|
| Humans | 45 | 2023 | 261506 | 0.180 |
Why?
|
| Risk Factors | 9 | 2021 | 17523 | 0.180 |
Why?
|
| Lipids | 2 | 2022 | 644 | 0.180 |
Why?
|
| Expert Testimony | 1 | 2020 | 90 | 0.180 |
Why?
|
| Deprescriptions | 1 | 2019 | 24 | 0.170 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2021 | 192 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 1362 | 0.170 |
Why?
|
| Inappropriate Prescribing | 1 | 2019 | 50 | 0.170 |
Why?
|
| Risk Assessment | 7 | 2021 | 6869 | 0.160 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 1148 | 0.150 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2016 | 75 | 0.140 |
Why?
|
| Cholesterol, HDL | 2 | 2010 | 341 | 0.140 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2015 | 56 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2020 | 712 | 0.130 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2021 | 563 | 0.130 |
Why?
|
| Pharmacists | 1 | 2015 | 95 | 0.130 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2015 | 84 | 0.120 |
Why?
|
| Lower Extremity | 1 | 2017 | 299 | 0.120 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2016 | 105 | 0.120 |
Why?
|
| Peripheral Arterial Disease | 1 | 2017 | 267 | 0.110 |
Why?
|
| Coronary Angiography | 1 | 2016 | 598 | 0.110 |
Why?
|
| Aged | 9 | 2022 | 70117 | 0.110 |
Why?
|
| Health Policy | 1 | 2015 | 291 | 0.110 |
Why?
|
| Disease Management | 2 | 2015 | 1052 | 0.100 |
Why?
|
| Aortic Valve | 1 | 2015 | 581 | 0.100 |
Why?
|
| Managed Care Programs | 2 | 2022 | 74 | 0.100 |
Why?
|
| Observational Studies as Topic | 2 | 2021 | 140 | 0.100 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2016 | 342 | 0.100 |
Why?
|
| Biomarkers | 5 | 2021 | 5047 | 0.100 |
Why?
|
| Global Health | 2 | 2019 | 657 | 0.100 |
Why?
|
| Achievement | 1 | 2010 | 41 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2015 | 795 | 0.090 |
Why?
|
| Health Personnel | 1 | 2015 | 625 | 0.090 |
Why?
|
| Patient Care | 1 | 2010 | 149 | 0.090 |
Why?
|
| Anticoagulants | 1 | 2015 | 787 | 0.090 |
Why?
|
| Health Care Surveys | 1 | 2010 | 430 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2010 | 597 | 0.080 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 719 | 0.080 |
Why?
|
| Medicare | 2 | 2022 | 860 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 1 | 2010 | 289 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 524 | 0.070 |
Why?
|
| Triglycerides | 1 | 2010 | 603 | 0.070 |
Why?
|
| Hospitals | 1 | 2010 | 485 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2022 | 37905 | 0.070 |
Why?
|
| Female | 8 | 2023 | 141928 | 0.070 |
Why?
|
| Treatment Outcome | 7 | 2021 | 32848 | 0.060 |
Why?
|
| Cholesterol, VLDL | 1 | 2004 | 18 | 0.060 |
Why?
|
| Middle Aged | 4 | 2020 | 86204 | 0.060 |
Why?
|
| Comorbidity | 2 | 2021 | 2352 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 2594 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2010 | 851 | 0.060 |
Why?
|
| Male | 5 | 2020 | 123000 | 0.060 |
Why?
|
| Multimorbidity | 1 | 2022 | 22 | 0.060 |
Why?
|
| Adult | 4 | 2021 | 77950 | 0.050 |
Why?
|
| United States Department of Defense | 1 | 2021 | 9 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 60 | 0.050 |
Why?
|
| Protective Factors | 1 | 2021 | 106 | 0.050 |
Why?
|
| Committee Membership | 1 | 2020 | 4 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 4892 | 0.050 |
Why?
|
| Patient Care Management | 1 | 2021 | 94 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 29902 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2000 | 120 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 333 | 0.040 |
Why?
|
| Aorta | 1 | 2023 | 692 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2021 | 749 | 0.040 |
Why?
|
| Sequestering Agents | 1 | 2017 | 2 | 0.040 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2000 | 314 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 586 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2021 | 605 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2018 | 149 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2021 | 703 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2010 | 9244 | 0.040 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 386 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2021 | 935 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2017 | 241 | 0.030 |
Why?
|
| Forecasting | 1 | 2019 | 694 | 0.030 |
Why?
|
| Classification | 1 | 2015 | 41 | 0.030 |
Why?
|
| Drug-Eluting Stents | 1 | 2016 | 131 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2015 | 117 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 313 | 0.030 |
Why?
|
| Morbidity | 1 | 2014 | 397 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 4314 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 622 | 0.020 |
Why?
|
| Pregnancy | 1 | 2023 | 7573 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 1879 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 5673 | 0.020 |
Why?
|
| Time Factors | 1 | 2021 | 12926 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 980 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 289 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 1323 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2006 | 383 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2008 | 661 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 3441 | 0.010 |
Why?
|
| Adolescent | 1 | 2021 | 31252 | 0.010 |
Why?
|
| Prognosis | 1 | 2014 | 21713 | 0.010 |
Why?
|